Cellforma develops regenerative cell therapies to provide life-saving treatments for patients suffering from fatal lung diseases. The company addresses the critical shortage of donor lungs by creating viable alternatives through advanced cell replacement technology.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with fatal lung diseases face a critical shortage of donor lungs, limiting access to life-saving treatments. The lack of available organs results in long waiting lists and high mortality rates for individuals with end-stage respiratory conditions.
Solution
Cellforma is developing regenerative cell therapies as viable alternatives to donor lungs, addressing the unmet need for effective treatments for fatal lung diseases. The company's advanced cell replacement technology aims to create functional lung tissue, offering a potential solution to the organ shortage crisis. By engineering healthy lung cells, Cellforma seeks to provide patients with new, functional lung tissue, improving their chances of survival and quality of life. This approach has the potential to eliminate the need for donor organs and revolutionize the treatment of end-stage lung diseases.
Target Audience
The primary target audience includes patients suffering from fatal lung diseases who are in need of lung transplants or alternative treatments.
Features
- Development of regenerative cell therapies for lung diseases
- Advanced cell replacement technology to create functional lung tissue